Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145551

Pw145551 View Pathway
drug action

Dequalinium Drug Metabolism Action Pathway

Homo sapiens

PW145180

Pw145180 View Pathway
drug action

Deserpidine Drug Metabolism Action Pathway

Homo sapiens

PW145276

Pw145276 View Pathway
drug action

Desflurane Drug Metabolism Action Pathway

Homo sapiens

PW127733

Pw127733 View Pathway
drug action

Desflurane GABA(A) Anesthetic Action Pathway

Homo sapiens
Desflurane is a general inhalation anesthetic for inpatient and outpatient surgery in adults. It can be found under the brand name Suprane, and is a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic. The mechanism of inhalational anesthetics is still not fully understood. They can block excitatory ion channels and increase the activity of inhibitory ion channels. The most notable agonism is at the GABAA channel. Desflurane is also an agonist of glycine receptors, antagonist of glutamate receptors, inducer of potassium voltage gated channels, and inhibits both NADH-ubiquinone oxioreductase chain and calcium transporting ATPases. Some side effects of using desflurane may include bluish lips and/or skin, body aches, and congestion.

PW126676

Pw126676 View Pathway
drug action

Desipramine (New) Drug Action

Homo sapiens

PW000425

Pw000425 View Pathway
drug action

Desipramine Action Pathway

Homo sapiens
Desipramine is a tricyclic antidepressant that exerts its therapeutic effects by inhibiting norepinephrine and serotonin reuptake in the brain. It does so by competing for the same binding site as norepinephrine on the sodium-dependent noradraneline transporter (SLC6A2) and by competing with serotonin for binding to the sodium-dependent serotonin transporter (SLC6A4). This increases the concentrations of both norepinephrine and serotonin in their respective synapses and reverses the state of low concentrations of both neurotransmitters found in depression. Higher concentrations of norepinephrine and serotonin have also been shown to have long-term neuromodulatory effects. Binding of these neurotransmitters to their respective receptors activate adenylate cyclase, which produces cAMP. cAMP activates protein kinase A which activates cAMP-responsive binding protein 1 (CREB-1). CREB-1 enters the nucleus and affects transcription of brain-derived neurotrophic factor (BDNF). BDNF subsequently stimulates neurogenesis, which may contribute to the long-term reversal of depression.

PW127947

Pw127947 View Pathway
drug action

Desipramine Action Pathway (New)

Homo sapiens
Desipramine, also known as Norpramin, is a dibenzazepine-derivative tricyclic antidepressant (TCA) used in the treatment of depression. In non-depressed individuals, desipramine does not affect mood but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. Secondary amine TCAs, such as desipramine, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs. It can also be used to manage chronic neuropathic pain, as a second-line agent for the management of anxiety disorders, and as a second or third-line agent in ADHD management. This drug is the active metabolite of imipramine, a tertiary amine TCA. It binds to the sodium-dependent noradrenaline transporter and to the sodium-dependent serotonin transporter of the presynaptic neurons. In consequence, there is a high concentration of those two neurotransmitters in the synapses. This molecule is administered as an oral tablet.

PW145239

Pw145239 View Pathway
drug action

Desipramine Drug Metabolism Action Pathway

Homo sapiens

PW000602

Pw000602 View Pathway
drug metabolism

Desipramine Metabolism Pathway

Homo sapiens
Desipramine is a tricyclic antidepressant that exerts its therapeutic effects by inhibiting norepinephrine and serotonin reuptake in the brain. It does so by competing for the same binding site as norepinephrine on the sodium-dependent noradraneline transporter (SLC6A2) and by competing with serotonin for binding to the sodium-dependent serotonin transporter (SLC6A4). This increases the concentrations of both norepinephrine and serotonin in their respective synapses and reverses the state of low concentrations of both neurotransmitters found in depression. Higher concentrations of norepinephrine and serotonin have also been shown to have long-term neuromodulatory effects. Binding of these neurotransmitters to their respective receptors activate adenylate cyclase, which produces cAMP. cAMP activates protein kinase A which activates cAMP-responsive binding protein 1 (CREB-1). CREB-1 enters the nucleus and affects transcription of brain-derived neurotrophic factor (BDNF). BDNF subsequently stimulates neurogenesis, which may contribute to the long-term reversal of depression.

PW128032

Pw128032 View Pathway
drug action

Desirudin Action Pathway

Homo sapiens
Desirudin is an inhibitor of thrombin, similar in structure to hirudin a naturally occurring anticoagulant peptide produced by salivary glands in leeches. This drug is administered to prevent deep vein thrombosis, some possible side effects include bleeding gums, blood collecting under the skin, coughing up blood, bruising and difficulty breathing and or swallowing. Desirudin binds to the active site of thrombin inhibiting the conversion of fibrinogen to fibrin, due to this stopping the formation of a blood clot. This is usually administered subcutaneously, it is then metabolized and eliminated via the kidney. Due to the anticoagulant properties herbs and supplements with anticoagulant and antiplatelet activity should be avoided, this includes ginger, garlic, bilberry, danshen, piracetam and ginkgo biloba.